The U.S. Food and Drug Administration authorized four new on! nicotine pouch products on August 4 through the premarket tobacco product application (PMTA) pathway, bringing the total of FDA-authorized nicotine pouches to 30.
The newly authorized products, manufactured by Helix Innovations LLC, are Rich Berry 2 mg, Cappuccino 2 mg, Cappuccino 4 mg, and Autumn Spice 2 mg. The FDA reviewed them under its nicotine pouch pilot program, which is designed to speed up PMTA reviews, and said lessons from the pilot are now being applied to other PMTA reviews.
The FDA concluded that the authorized products contain lower levels of most harmful and potentially harmful constituents than traditional oral and smokeless tobacco products. Adults 21 and older who completely switch from cigarettes or smokeless tobacco to FDA-authorized nicotine pouches may reduce their exposure to harmful chemicals, the agency said.
The FDA cautioned that dual use, using nicotine pouches alongside cigarettes, does not provide the same level of risk reduction as complete switching. The American Heart Association criticized the decision, saying that authorizing flavored pouches threatens to sustain youth nicotine use.
Adults who are new to pouches can start with our guide to using nicotine pouches.
Sources
– FDA CTP Newsroom (August 4, 2026): Pilot Program Update: FDA Authorizes 4 New Nicotine Pouches – Healio (August 5, 2026): FDA authorizes sale of four on! nicotine pouches – American Heart Association (August 3, 2026): FDA authorization of flavored nicotine pouches threatens to sustain youth nicotine use – Tobacco Reporter (August 4, 2026): FDA authorizes four new on! nicotine pouches
Kevin Li — Founder & Editor, VapeObservation.com Kevin reviews vape products hands-on, prioritizing real-world performance over manufacturer claims. His goal: honest, practical advice that helps everyday vapers make informed choices. Before launching VapeObservation, he was a longtime vaper frustrated by promotional content disguised as reviews. Every article on the site reflects his commitment to data-driven, reader-first testing.
